Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B

Journal of Infectious Diseases

Volumn 181, Issue 4, 2000, Pages 1221-1233

  Seignères, Béatrice ^a   Pichoud, Christian ^a   Ahmed, Sinafa Si ^a   Hantz, Olivier ^a   Trépo, Christian ^a   Zoulim, Fabien ^a,b  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; VIRUS RESISTANCE;

2-AMINOPURINE; ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CLONING, MOLECULAR; DRUG RESISTANCE, MICROBIAL; EVOLUTION, MOLECULAR; FEMALE; GENE PRODUCTS, POL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ALIGNMENT;

EID: 0034062371     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315368     Document Type: Article

References (40)

1. 1. Günther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25-137.
2. 2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-45.
3. 3. Summers J, Mason WS. Replication of the genome of a hepatitis B like virus by reverse transcription of an RNA intermediate. Cell 1982; 29:403-15.
4. 4. Norder H, Couroucé AM, Magnius L. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198:489-503.
5. 5. Zoulim F, Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998; 29:151-68.
6. 6. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657-61.
7. 7. Trépo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study [abstract 247]. Hepatology 1996; 24:188A.
8. 8. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9.
9. 9. Mason WS, Cullen J, Moraleda G, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998; 245:18-32.
10. 10. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93:4398-402.
11. 11. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-3.
12. 12. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-7.
13. 13. Lai CL, Chine RW, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
14. 14. Arts E, Wainberg M. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996; 40:527-40.
15. 15. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994; 47:155-69.
16. 16. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-7.
17. 17. Chayama K, Suzuki Y, Kobayashi M, et al. Fmergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-take-over by wild type after cessation of therapy. Hepatology 1998; 27:1711-6.
18. 18. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-33.
19. 19. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103:1635-40.
20. 20. Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57:1351-9.
21. 21. Aye TT, Bartholomeusz A, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:1148-53.
22. 22. Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News 1997; 5:123-4.
23. 23. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40:337-42.
24. 24. Pichoud C, Seignères H, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29: 230-7.
25. 25. Tillmann HL, Trautwein C, Bock T, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30:244-56.
26. 26. Locarnini SA, Aye TT, Shaw T, et al. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation [abstract 958]. Hepatology 1997; 26:368A.
27. 27. Shaw T, Mok S, Locarnini S. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hcpatology 1996; 24: 996-1002.
28. 28. Dannaoui E, Trépo C, Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antiviral Chem Chemother 1997; 8:38-46.
29. 29. Allen MI, Gauthier J, Deslauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microb 1999; 37:3338-47.
30. 30. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994; 68:6-13.
31. 31. Argentini C, La Sorsa V, Bruni R, D'Ugo E, Giuseppetti R, Rapicetta M. Hepadnavirus evolution and molecular strategy of adaptation in a new host. J Gen Virol 1999; 80:617-26.
32. 32. Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28:555-61.
33. 33. Bartenschlager R, Schaller H. The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J 1988; 7:4185-92.
34. 34. Günther S, von Breunig F, Santantonio T, et al. Absence of mutations in the YMDD motif/B region or the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999; 30:749-54.
35. 35. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177:1382-5.
36. 36. Hu J, Toft D, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J 1997; 16:59-68.
37. 37. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution if HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783-90.
38. 38. Lai CL, Yuen MF, Cheng CC, Wong WM, Cheng TK, Lai YP. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B infection [abstract 622]. Hepatology 1998; 28:318A.
39. 39. Carman W. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4:11-20.
40. 40. Mangold CM, Unckell F, Werr M, Streeck RE. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 1995; 211:535-43.